Sintx Rises After First Use Of Fda: cleared implant, names new president

SINTX Technologies

23/03/2026 13:59

** Shares of biomaterials maker SINTX Technologies SINT.O rise 7% to $2.75

** Co says a surgeon performed the first human surgery using its FDA-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, marking SINTX's entry into the foot and ankle reconstruction market

** The system is used to correct bone alignment problems in the foot and ankle, a common issue linked to joint damage and deformities, co says

** Says it also named Ryan Elmore as president to lead commercialization and revenue growth efforts

** Co says it is preparing for commercial rollout of the SINAPTIC wedge system and targeting revenue growth in 2026 after streamlining operations and raising about $10 million over the past year

** Says it is expanding manufacturing, including AI‑assisted 3D printing, and exploring new uses of its silicon nitride beyond implants

** Share up ~10% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))